Curated Wealth Partners LLC Purchases Shares of 4,112 DexCom, Inc. $DXCM

Key Points

• Curated Wealth Partners LLC purchased 4,112 shares of DexCom, Inc. valued at approximately $359,000 in the second quarter, contributing to the institutional ownership of 97.75% of the company’s stock.
• DexCom reported a quarterly earnings per share of $0.48, surpassing analysts' expectations, and its revenue reached $1.16 billion, marking a 15.2% increase compared to the previous year.
• Several analysts have adjusted their price targets for DexCom, with UBS Group setting it at $106, reflecting a positive outlook for the company's stock performance.

Curated Wealth Partners LLC purchased a new stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 4,112 shares of the medical device company's stock, valued at approximately $359,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Golden State Wealth Management LLC raised its holdings in shares of DexCom by 211.2% during the first quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company's stock valued at $27,000 after acquiring an additional 264 shares in the last quarter. Zions Bancorporation National Association UT bought a new position in DexCom in the first quarter worth about $27,000. Anderson Financial Strategies LLC bought a new position in DexCom in the first quarter worth about $37,000. Alpine Bank Wealth Management bought a new position in DexCom in the first quarter worth about $40,000. Finally, Private Trust Co. NA raised its position in shares of DexCom by 99.4% in the 1st quarter. Private Trust Co. NA now owns 672 shares of the medical device company's stock worth $46,000 after acquiring an additional 335 shares in the last quarter. Institutional investors own 97.75% of the company's stock.

DexCom Stock Up 1.5%

NASDAQ:DXCM opened at $66.21 on Wednesday. The firm has a market cap of $25.96 billion, a P/E ratio of 45.98, a P/E/G ratio of 1.37 and a beta of 1.47. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.35 and a current ratio of 1.52. DexCom, Inc. has a fifty-two week low of $57.52 and a fifty-two week high of $93.25. The firm has a 50-day simple moving average of $74.01 and a two-hundred day simple moving average of $77.62.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its quarterly earnings results on Wednesday, July 30th. The medical device company reported $0.48 earnings per share for the quarter, beating the consensus estimate of $0.45 by $0.03. The company had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The firm's quarterly revenue was up 15.2% compared to the same quarter last year. During the same quarter last year, the firm earned $0.43 earnings per share. DexCom has set its FY 2025 guidance at EPS. Analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other DexCom news, Director Mark G. Foletta sold 2,750 shares of DexCom stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $81.06, for a total value of $222,915.00. Following the completion of the sale, the director owned 51,121 shares of the company's stock, valued at approximately $4,143,868.26. The trade was a 5.10% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Kyle Malady sold 667 shares of DexCom stock in a transaction that occurred on Friday, September 5th. The stock was sold at an average price of $80.86, for a total transaction of $53,933.62. Following the completion of the sale, the director directly owned 22,667 shares of the company's stock, valued at approximately $1,832,853.62. This trade represents a 2.86% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 6,849 shares of company stock valued at $564,733 over the last quarter. Corporate insiders own 0.32% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the company. UBS Group increased their target price on DexCom from $105.00 to $106.00 and gave the stock a "buy" rating in a research report on Thursday, July 31st. Mizuho increased their price target on shares of DexCom from $95.00 to $100.00 and gave the stock an "outperform" rating in a research note on Wednesday, July 16th. Robert W. Baird decreased their price target on shares of DexCom from $112.00 to $90.00 and set an "outperform" rating for the company in a research note on Friday, September 26th. Morgan Stanley raised their target price on shares of DexCom from $82.00 to $89.00 and gave the company an "equal weight" rating in a research note on Tuesday, July 15th. Finally, The Goldman Sachs Group decreased their target price on shares of DexCom from $104.00 to $89.00 and set a "buy" rating for the company in a research note on Wednesday, October 1st. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and six have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, DexCom has an average rating of "Moderate Buy" and an average target price of $97.42.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.